TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
Abstract
BACKGROUND In this retrospective study we evaluated effectiveness and safety of bortezomib, comparingour results with already published clinical studies. METHODS Patients received bortezomib as part of everyday clinical practice and in the range ofapproved indications. We evaluated bortezomib effectiveness in 66 patients according tomodified SWOG criteria and treatment responsiveness (CR, VGPR, PR, MR) or unresponsiveness (SD, PD). Treatment responsiveness was compared according to high risk (beta-2microglobulin ? 5,5 mg/L) or standard risk (beta-2 mikroglobulin < 5.5 mg/L), patient’sage (> 65 ali < 65 let), number of previous treatments (1 ali > 1) and previous treatmentwith thalidomid. Side effects and reasons for early treatment discontinuation were alsoevaluated. RESULTS Patients received 1–7 previous treatments (median 1.5). Treatment responsiveness wasobserved in 80.3 % patients (1.5 % CR, 45.5 % VGPR, 21.2 % PR and 12.1 % MR). Nostatistical significant influence was observed according to: high risk (p = 0.178), age above65 years (p = 0.756), > 1 previous treatment (p = 0.419) or previous treatment with thalidomid (p = 0.475). Side effects of bortezomib treatment were: anemia (40.9 %), peripheralneuropathy grade 3 or more (28.7 %), infections (21.2 %), herpes zooster (12.1 %), neutropenia (10.6 %), trombocitopenia (9 %) and gastro-intestinal problems (7.5 %). Earlydiscontinuation was observed due to: peripheral neuropathy (28.7 %), other seriousside effects (6 %), bortezomib uneffectiveness (19.7 %) or planned autologous transplant(15.1 %). CONCLUSIONS Bortezomib (Velcade) is effective and safe treatment also for patients with multiple myeloma that developed resistance to previous treatments or belong to high risk patient groupDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
